MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Status:
Active, not recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
In the first phase of this study (Cohort 1), the investigators will determine the feasibility
of adding MRSI to the evaluation of newly-diagnosed GBM patients treated with standard RT/TMZ
and determine whether magnetic resonance spectroscopic imaging (MRSI) can predict for better
outcomes in these patients. In the second phase of this study (Cohorts 2a and 2b), the
investigators will find the maximum tolerated dose of belinostat for treating newly-diagnosed
GBM patients with standard RT/TMZ and will determine whether MRSI can aid clinicians in the
early determination of response to this new therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
Johns Hopkins University National Cancer Institute (NCI) National Institute of Neurological Disorders and Stroke (NINDS) Spectrum Pharmaceuticals, Inc